Syntekabio and Enamine partner for AI-based drug development

Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.

Sep 4, 2024 - 04:00

Syntekabio and Enamine partner for AI-based drug development

Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.

Read the original article

Tags:

Previous Article

Why the Importer of Record (IoR) is vital in the clinical supply chain

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: Filling 12-month prescriptions is one practical way to help the pharmacist crisis

Opinion: Filling 12-month prescriptions is one practica...

Nov 21, 2023

AI and stable funding environments are catalysts for biotech assets

AI and stable funding environments are catalysts for bi...

Jun 28, 2024

STAT+: 3 FDA staffers to watch in 2024

STAT+: 3 FDA staffers to watch in 2024

Dec 27, 2023